Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 21 results
Author
Title
[
Type
]
Year
Filters:
First Letter Of Last Name
is
B
[Clear All Filters]
Journal Article
Boussi L
,
Niesvizky R
. 2017.
Advances in immunotherapy in multiple myeloma.
.
Curr Opin Oncol. 29(6):460-466.
Badros AZ
,
Vij R
,
Martin T
,
Zonder JA
,
Kunkel L
,
Wang Z
,
Lee S
,
Wong AF
,
Niesvizky R
. 2013.
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.
.
Leukemia. 27(8):1707-14.
A Stewart K
,
S Rajkumar V
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Mihaylov GG
et al.
. 2015.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
.
N Engl J Med. 372(2):142-52.
A Stewart K
,
S Rajkumar V
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Mihaylov GG
et al.
. 2015.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
.
N Engl J Med. 372(2):142-52.
Avet-Loiseau H
,
Fonseca R
,
Siegel D
,
Dimopoulos MA
,
Spicka I
,
Masszi T
,
Hajek R
,
Rosiñol L
,
Goranova-Marinova V
,
Mihaylov G
et al.
. 2016.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
.
Blood. 128(9):1174-80.
Avet-Loiseau H
,
Fonseca R
,
Siegel D
,
Dimopoulos MA
,
Spicka I
,
Masszi T
,
Hajek R
,
Rosiñol L
,
Goranova-Marinova V
,
Mihaylov G
et al.
. 2016.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
.
Blood. 128(9):1174-80.
Braunstein M
,
Niesvizky R
. 2016.
Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.
.
Semin Oncol. 43(6):709-711.
Wei X
,
M Calvo-Vidal N
,
Chen S
,
Wu G
,
Revuelta MV
,
Sun J
,
Zhang J
,
Walsh MF
,
Nichols KE
,
Joseph V
et al.
. 2018.
Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.
.
Cancer Res. 78(10):2747-2759.
A Stewart K
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Niesvizky R
,
Jakubowiak AJ
et al.
. 2016.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
.
J Clin Oncol. 34(32):3921-3930.
Nayar U
,
Sadek J
,
Reichel J
,
Hernandez-Hopkins D
,
Akar G
,
Barelli PJ
,
Sahai MA
,
Zhou H
,
Totonchy J
,
Jayabalan D
et al.
. 2017.
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.
.
J Clin Invest. 127(6):2066-2080.
Castillo JJ
,
Jurczyszyn A
,
Brozova L
,
Crusoe E
,
Czepiel J
,
Davila J
,
Dispenzieri A
,
Eveillard M
,
Fiala MA
,
Ghobrial IM
et al.
. 2017.
IgM myeloma: A multicenter retrospective study of 134 patients.
.
Am J Hematol. 92(8):746-751.
Siegel D
,
Martin T
,
Nooka A
,
R Harvey D
,
Vij R
,
Niesvizky R
,
Badros AZ
,
Jagannath S
,
McCulloch L
,
Rajangam K
et al.
. 2013.
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
.
Haematologica. 98(11):1753-61.
Kumar SK
,
Bensinger WI
,
Zimmerman TM
,
Reeder CB
,
Berenson JR
,
Berg D
,
Hui A-M
,
Gupta N
,
Di Bacco A
,
Yu J
et al.
. 2014.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
.
Blood. 124(7):1047-55.
Kumar SK
,
Bensinger WI
,
Zimmerman TM
,
Reeder CB
,
Berenson JR
,
Berg D
,
Hui A-M
,
Gupta N
,
Di Bacco A
,
Yu J
et al.
. 2014.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
.
Blood. 124(7):1047-55.
Kumar SK
,
Bensinger WI
,
Zimmerman TM
,
Reeder CB
,
Berenson JR
,
Berg D
,
Hui A-M
,
Gupta N
,
Di Bacco A
,
Yu J
et al.
. 2014.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
.
Blood. 124(7):1047-55.
Niesvizky R
,
Badros AZ
,
Costa LJ
,
Ely SA
,
Singhal SB
,
Stadtmauer EA
,
Haideri NA
,
Yacoub A
,
Hess G
,
Lentzsch S
et al.
. 2015.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
.
Leuk Lymphoma. 56(12):3320-8.
Wang M
,
Martin T
,
Bensinger W
,
Alsina M
,
Siegel DS
,
Kavalerchik E
,
Huang M
,
Orlowski RZ
,
Niesvizky R
. 2013.
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
.
Blood. 122(18):3122-8.
Ou Y
,
Doshi S
,
Nguyen A
,
Jonsson F
,
Aggarwal S
,
Rajangam K
,
Dimopoulos MA
,
A Stewart K
,
Badros A
,
Papadopoulos KP
et al.
. 2017.
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.
.
J Clin Pharmacol. 57(5):663-677.
Kumar SK
,
Berdeja JG
,
Niesvizky R
,
Lonial S
,
Laubach JP
,
Hamadani M
,
A Stewart K
,
Hari P
,
Roy V
,
Vescio R
et al.
. 2014.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
.
Lancet Oncol. 15(13):1503-12.
Kumar SK
,
Berdeja JG
,
Niesvizky R
,
Lonial S
,
Laubach JP
,
Hamadani M
,
A Stewart K
,
Hari P
,
Roy V
,
Vescio R
et al.
. 2014.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
.
Lancet Oncol. 15(13):1503-12.
Mark TM
,
Bowman IA
,
Rossi AC
,
Shah M
,
Rodriguez M
,
Quinn R
,
Pearse RN
,
Zafar F
,
Pekle K
,
Jayabalan D
et al.
. 2014.
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
.
Leuk Lymphoma. 55(12):2842-9.